About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company's TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: TTPH
- Previous Close: $5.20
- 50 Day Moving Average: $4.43
- 200 Day Moving Average: $4.05
- 52-Week Range: $3.11 - $6.28
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.18
- P/E Growth: -0.02
- Market Cap: $192.27M
- Outstanding Shares: 36,904,000
- Beta: 2.66
- Net Margins: -1,120.67%
- Return on Equity: -39.95%
- Return on Assets: -37.74%
Companies Related to Tetraphase Pharmaceuticals:
- Current Ratio: 15.54%
- Quick Ratio: 15.54%
What is Tetraphase Pharmaceuticals' stock symbol?
Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."
Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?
4 analysts have issued 1-year target prices for Tetraphase Pharmaceuticals' shares. Their predictions range from $4.00 to $7.00. On average, they expect Tetraphase Pharmaceuticals' share price to reach $5.67 in the next twelve months.
When will Tetraphase Pharmaceuticals announce their earnings?
Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Tetraphase Pharmaceuticals stock?
Tetraphase Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (5.33%), State Street Corp (1.93%), Eventide Asset Management LLC (1.63%), Renaissance Technologies LLC (0.96%), Dimensional Fund Advisors LP (0.61%) and Numeric Investors LLC (0.49%). Company insiders that own Tetraphase Pharmaceuticals stock include David Charles Lubner, Guy Macdonald, John Craig Thompson, L Patrick Gage and Patrick Taylor Horn.
Who sold Tetraphase Pharmaceuticals stock? Who is selling Tetraphase Pharmaceuticals stock?
Tetraphase Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Numeric Investors LLC and FMR LLC.
Who bought Tetraphase Pharmaceuticals stock? Who is buying Tetraphase Pharmaceuticals stock?
Tetraphase Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Russell Investments Group Ltd., Cigna Investments Inc. New, A.R.T. Advisors LLC, GSA Capital Partners LLP, State Street Corp, Teton Advisors Inc. and Federated Investors Inc. PA.
How do I buy Tetraphase Pharmaceuticals stock?
Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Tetraphase Pharmaceuticals stock cost?
One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $5.20.